Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones

2025.11.19 21:37

I'm PortAI, I can summarize articles.

Vertex Pharmaceuticals Inc. (VRTX) stock fell 3.33% to $421.03 on Wednesday, underperforming compared to competitors like AbbVie Inc. and Krystal Biotech Inc. Despite a favorable trading session for the market, VRTX closed 18.98% below its 52-week high of $519.68. The S&P 500 Index rose 0.38% and the Dow Jones Industrial Average rose 0.10%.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Vertex Pharmaceuticals Inc. (VRTX) slipped 3.33% to $421.03 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.38% to 6,642.16 and the Dow Jones Industrial Average rising 0.10% to 46,138.77. Vertex Pharmaceuticals Inc. closed 18.98% below its 52-week high of $519.68, which the company reached on March 14th. The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as AbbVie Inc. (ABBV) fell 0.41% to $232.91, Krystal Biotech Inc. (KRYS) fell 0.31% to $204.10, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 8.76% to $6.04. Data source: Dow Jones Market Data, FactSet. Data compiled November 19, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 11-19-25 1637ET